Cargando…
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
BACKGROUND: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not candi...
Autores principales: | Kanz, Bridgette A., Pollack, Megan H., Johnpulle, Romany, Puzanov, Igor, Horn, Leora, Morgans, Alicia, Sosman, Jeffrey A., Rapisuwon, Suthee, Conry, R. Martin, Eroglu, Zeynep, Johnson, Douglas B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067899/ https://www.ncbi.nlm.nih.gov/pubmed/27777770 http://dx.doi.org/10.1186/s40425-016-0166-5 |
Ejemplares similares
-
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017) -
High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018) -
Circulating biomarkers to monitor cancer progression and treatment
por: Rapisuwon, Suthee, et al.
Publicado: (2016) -
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy: Endomyocardial Biopsy Provides Pathological Insights to Dual Diseases
por: Serzan, Michael, et al.
Publicado: (2021) -
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
por: Li, Edward, et al.
Publicado: (2021)